DUBLIN and BRIDGEWATER, N.J. – Amarin (NASDAQ:AMRN) Corporation plc (NASDAQ:AMRN), a biopharmaceutical company with a market capitalization of approximately $192 million, announced today that Peter Fishman has been named the new Chief Financial Officer, effective immediately. According to InvestingPro data, the company's stock is currently trading near its 52-week low, suggesting potential value opportunity for investors. Fishman, who has nearly two decades of experience in finance, will lead the global finance organization and report directly to CEO Aaron Berg.
Fishman ascends to the CFO role after serving as Amarin's Global Controller and principal financial and accounting officer since October 2024. He joined the company in 2019 and has played a significant role in its financial operations, including previous financing efforts and the current cash management strategy. InvestingPro analysis shows the company maintains a strong current ratio of 3.23, with liquid assets exceeding short-term obligations.
Before his tenure at Amarin, Fishman held positions at Toys R Us in financial reporting and technical accounting. His career began at Ernst & Young, where he served several pharmaceutical clients. Fishman's educational background includes a Bachelor of Arts in accounting and an MBA, and he is a certified public accountant.
CEO Aaron Berg expressed confidence in Fishman's abilities to contribute to the company's financial and business strategy moving forward. This appointment comes at a time when Amarin is focused on expanding global access and reimbursement for its cardiovascular drug, VAZKEPA.
The press release also contained forward-looking statements regarding Amarin's achievements, financial outlook, and the potential success of VAZKEPA. These statements are subject to risks and uncertainties, and investors are cautioned against placing undue reliance on them.
Amarin regularly communicates with investors through various channels, including its website, investor relations pages, and SEC filings. The company has clarified that information posted on these channels is deemed material and encourages stakeholders to review them regularly.
This news article is based on a press release statement from Amarin Corporation plc.
In other recent news, Amarin Corporation has been granted an extension by Nasdaq to meet the exchange's minimum bid price requirement, according to an SEC filing. This development follows Amarin's ongoing efforts to maintain its standing on the stock exchange. In addition, the corporation's third-quarter revenue for 2024 reported a decrease due to increased competition from generic drugs in the U.S. market. Despite this, Amarin maintains a robust market share, with a strong focus on expanding access to its cardiovascular disease treatment, particularly in the European market. The company's financial position remains stable with $306 million in cash and investments. Furthermore, Amarin is actively pursuing partnerships to bolster international growth. These recent developments highlight the company's strategic efforts to navigate the competitive landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.